Zenas BioPharma to Present at Jefferies Conference

Zenas BioPharma, Inc. ( (ZBIO) ) just unveiled an announcement.

Zenas BioPharma announced its participation in the Jefferies Global Healthcare Conference in June 2025, where it will present its investor presentation. The company is advancing its clinical trials for Obexelimab, a potentially highly differentiated therapy for autoimmune diseases, with significant upcoming data readouts expected in late 2025 and mid-2026. These developments could position Zenas BioPharma as a competitive player in the biotechnology market, potentially impacting stakeholders positively.

The most recent analyst rating on (ZBIO) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Zenas BioPharma, Inc. stock, see the ZBIO Stock Forecast page.

Spark’s Take on ZBIO Stock

According to Spark, TipRanks’ AI Analyst, ZBIO is a Underperform.

Zenas BioPharma faces significant challenges with declining revenue, persistent operating losses, and substantial cash flow issues, resulting in a low financial performance score. The technical analysis indicates a bearish trend, and the negative P/E ratio underscores valuation concerns. The absence of earnings call and corporate events data limits further assessment, but the current data suggests a cautious outlook.

To see Spark’s full report on ZBIO stock, click here.

More about Zenas BioPharma, Inc.

Zenas BioPharma, Inc. operates in the biotechnology industry, focusing on developing therapies for autoimmune diseases. The company is working on creating a global immunology-based development and commercial biotechnology platform, with a particular emphasis on innovative treatments like Obexelimab, a bifunctional B cell targeting antibody.

Average Trading Volume: 184,631

Technical Sentiment Signal: Hold

Current Market Cap: $420.9M

See more data about ZBIO stock on TipRanks’ Stock Analysis page.